๐บ๐ธ Vivek Ramaswamy bought a failed Alzheimerโs drug for $5M, hyped it to a $3B valuation, and cashed out $40M
Retirees and pension funds poured in billions.
Trials showed zero benefits, with no improvement in memory, thinking, or daily activities.
The stock crashed 90%